Does Regence Cover Eliquis?

What Regence Covers and Why Eliquis Is on the Formulary

Regence BlueCross BlueShield covers Eliquis on its commercial formularies in Idaho, Oregon, Utah, and Washington, as well as on its Medicare Advantage and individual marketplace plans. Coverage is not automatic at the pharmacy counter. Most Regence plans place apixaban on Tier 3 or Tier 4, requiring members to meet prior authorization (PA) criteria before the plan will pay its share of the drug's cost.

Why Apixaban Lands on a Higher Tier

Formulary tiering decisions reflect both clinical evidence and negotiated drug pricing. Apixaban has no FDA-approved generic competitor as of early 2025. Because branded-only drugs carry higher list prices, insurers including Regence place them on higher tiers to steer prescribing toward lower-cost alternatives such as warfarin or, in some cases, rivaroxaban, which may have different rebate agreements. The FDA's Orange Book confirms apixaban's patent protection remains active, which is why no generic appears on any major formulary. [1]

Which Plan Types Include Eliquis

Coverage varies by product line. Regence EmployeeChoice (large employer) plans, Regence individual and family plans (ACA marketplace), Regence MedAdvantage plans, and Regence Medicare Supplement plans that coordinate with Part D all list Eliquis. Federal Employee Program (FEP) plans administered by Regence follow a separate formulary determined by the Office of Personnel Management, where Eliquis has historically appeared on Tier 3. Members should pull the current-year Summary of Benefits and Coverage or call the member services number on their ID card to confirm their specific plan's tier.

Prior Authorization Requirements for Eliquis on Regence Plans

Prior authorization is required on the majority of Regence commercial and Medicare Advantage plans for Eliquis. This is not a denial. It is a clinical review step to confirm the prescribing indication matches FDA-approved uses and Regence's coverage criteria.

Conditions That Typically Satisfy PA Criteria

Regence generally approves PA requests for Eliquis when documentation confirms one of the following:

• Nonvalvular atrial fibrillation (AF) with elevated stroke risk. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year, hazard ratio 0.79, 95% CI 0.66 to 0.95, P<0.001 for superiority). [2] The American Heart Association's 2023 AF guideline gives apixaban a Class I recommendation for stroke prevention in patients with CHA2DS2-VASc scores of 2 or higher in men and 3 or higher in women. [3]

• Deep vein thrombosis (DVT) or pulmonary embolism (PE) treatment. The AMPLIFY trial (N=5,395) showed apixaban 10 mg twice daily for 7 days, then 5 mg twice daily, was non-inferior to conventional anticoagulation for recurrent VTE (2.3% vs. 2.7%, relative risk 0.84, 95% CI 0.60 to 1.18) with significantly fewer major bleeding events (0.6% vs. 1.8%, P<0.001). [4] The American College of Chest Physicians (CHEST) 2021 antithrombotic guidelines recommend direct oral anticoagulants (DOACs) such as apixaban over vitamin K antagonists for most patients with DVT or PE. [5]

• VTE prophylaxis after elective hip or knee replacement. FDA labeling for Eliquis specifies 2.5 mg twice daily beginning 12 to 24 hours post-op. [6]

What Happens If PA Is Denied

A denial is not permanent. Physicians can submit a peer-to-peer review request, and patients have the right to file a formal appeal under the plan's internal review process. If the internal appeal fails, external independent review is available under ACA provisions for marketplace plans. Medicare Advantage members can request a Coverage Determination, then an Independent Review Entity (IRE) review through CMS processes outlined in the Medicare Appeals regulations. [7]

Step Therapy Policies

Some Regence plans impose step therapy, requiring a trial of warfarin or another anticoagulant before Eliquis will be approved. Step therapy overrides are available when a provider documents a clinical reason apixaban is preferable, such as labile INR on warfarin, patient inability to manage INR monitoring, or drug-drug interactions contraindicated with warfarin. The 2019 CMCS informational bulletin from CMS outlines step therapy override protections for Medicare Advantage enrollees. [8]

How Much Does Eliquis Cost With Regence Coverage?

Cost depends on tier placement, the plan's annual deductible phase, and whether a member has reached their out-of-pocket maximum. Without any assistance programs, Eliquis can cost $530, $600 per 30-day supply at retail. With Regence coverage at Tier 3, typical commercial cost-sharing runs $50, $110 per 30-day fill, though this varies.

Co-Pay Cards for Commercial Members

Bristol-Myers Squibb and Pfizer offer a co-pay assistance program through the Eliquis 360 Support program. Eligible commercially insured patients may pay as little as $10 per month for a 30-day supply, with a maximum benefit of $6,400 per calendar year. Co-pay cards are not usable by Medicare or Medicaid enrollees, as federal anti-kickback statutes restrict manufacturer assistance for government-insured patients. [9]

Medicare Part D and the Low-Income Subsidy

For Regence MedAdvantage members with Part D drug benefits, Eliquis coverage falls under the plan's standard Part D formulary. In 2025, the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D beneficiaries applies, which meaningfully limits maximum exposure for high-cost drugs like Eliquis. [10] Patients who qualify for the Extra Help (Low-Income Subsidy) program through the Social Security Administration may pay $0, $11.20 per month. [11]

Patient Assistance Programs for Uninsured or Underinsured Patients

The Bristol-Myers Squibb Patient Assistance Foundation provides free Eliquis to patients who meet income eligibility requirements and lack adequate drug coverage. Applications are processed through the foundation directly, and a provider prescription is required. [12]

Clinical Background: Why Eliquis Is Prescribed and Why Coverage Matters

Apixaban belongs to the direct oral anticoagulant (DOAC) class and works by selectively inhibiting Factor Xa, blocking the conversion of prothrombin to thrombin without requiring routine INR monitoring. The drug's predictable pharmacokinetics and twice-daily dosing produce stable anticoagulation for most patients.

Atrial Fibrillation and Stroke Risk

Approximately 2.7 million Americans live with atrial fibrillation, and the condition accounts for roughly 15 to 20% of all ischemic strokes annually, according to CDC surveillance data. [13] Stroke prevention is the primary driver of long-term Eliquis prescribing. The ARISTOTLE trial's finding of a 31% reduction in hemorrhagic stroke versus warfarin (0.24% vs. 0.47% per year, P<0.001) [2] is clinically significant because hemorrhagic strokes carry far higher mortality than ischemic events.

The American Heart Association's 2023 Guideline for Diagnosis and Management of Atrial Fibrillation states: "For patients with AF and at least one risk factor for stroke, oral anticoagulation is recommended. Among the available agents, apixaban demonstrated the lowest rates of stroke, systemic embolism, and mortality in randomized controlled trials." [3]

VTE Treatment and Secondary Prevention

VTE affects an estimated 900,000 Americans annually, with approximately 60,000 to 100,000 dying from PE each year, based on CDC estimates. [14] Anticoagulation is the cornerstone of treatment. The AMPLIFY-EXT trial (N=2,486), an extension of AMPLIFY, showed apixaban 2.5 mg twice daily for 12 months after initial treatment reduced recurrent VTE by 81% compared to placebo (3.8% vs. 11.6%, relative risk 0.33, 95% CI 0.22 to 0.48, P<0.001) without a significant increase in major bleeding. [15]

The American College of Chest Physicians' guidelines note: "In patients with provoked or unprovoked DVT or PE who complete initial anticoagulation, extended therapy is recommended when the bleeding risk is acceptable, and a DOAC is preferred over warfarin." [5]

Renal Dosing Considerations

Apixaban dosing requires adjustment in certain patients. The standard dose reduction to 2.5 mg twice daily applies when a patient meets at least two of the following three criteria: age 80 or older, body weight 60 kg or below, or serum creatinine 1.5 mg/dL or higher. [6] This reduced dose is supported by population pharmacokinetic modeling included in the FDA-approved prescribing information. Because renal function affects apixaban clearance, patients with end-stage renal disease on dialysis present a specific clinical challenge, and prescribers should consult the full labeling. [6]

Comparing Eliquis to Other Anticoagulants on the Regence Formulary

Not every anticoagulant prescription will require Eliquis specifically. Regence formularies typically offer warfarin, rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa) as alternatives at various tiers. The table below summarizes relative positioning and key clinical differences.

| Drug | Mechanism | Dosing Frequency | Typical Regence Tier | Monitoring Required | |---|---|---|---|---| | Warfarin (generic) | Vitamin K antagonist | Once daily (variable) | Tier 1 | Yes, regular INR | | Apixaban (Eliquis) | Factor Xa inhibitor | Twice daily | Tier 3 to 4 | No routine labs | | Rivaroxaban (Xarelto) | Factor Xa inhibitor | Once daily (indication-dependent) | Tier 3 to 4 | No routine labs | | Dabigatran (Pradaxa) | Direct thrombin inhibitor | Twice daily | Tier 3 to 4 | No routine labs | | Edoxaban (Savaysa) | Factor Xa inhibitor | Once daily | Tier 3 to 4 | No routine labs |

Warfarin's generic status places it at Tier 1 on virtually every formulary. Its lower cost is offset by the need for regular INR monitoring and significant drug-food interactions. A 2023 meta-analysis of 11 trials (N=102,358 total patients) published in the European Heart Journal confirmed that DOACs as a class reduce all-cause mortality by 10% compared with warfarin in patients with AF (OR 0.90, 95% CI 0.85 to 0.95). [16] Within the DOAC class, cross-trial comparisons favor apixaban on bleeding outcomes, though direct head-to-head trials with consistent populations are limited.

Rivaroxaban has once-daily dosing for most AF and VTE maintenance indications, which some patients prefer. The ROCKET AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention in AF (HR 0.88, 95% CI 0.74 to 1.03 in the per-protocol analysis). [17] Prescribers and patients choose between these agents based on dosing preference, bleeding history, renal function, and cost.

How to Get Eliquis Covered Through Regence: A Step-by-Step Approach

Getting Eliquis approved through Regence is manageable with the right documentation. The process typically takes 3 to 14 business days for a standard PA review.

Step 1: Confirm Your Plan's Formulary Status

Log into your Regence member portal at regence.com and use the drug search tool to verify the current tier and PA requirements for apixaban on your specific plan. Formularies update annually on January 1, so checking at the start of each plan year matters. The CMS requires that Part D plan formularies be publicly accessible. [18]

Step 2: Have Your Provider Submit PA Documentation

Your prescribing physician submits a PA request to Regence, typically through the plan's online portal or by fax. Required documentation generally includes:

• Diagnosis code (e.g., I48.x for atrial fibrillation, I82.x for DVT, I26.x for PE)
• Clinical notes confirming the diagnosis
• CHA2DS2-VASc score for AF patients
• History of prior anticoagulant use and reason for switching, if applicable
• Any contraindications to alternatives

Step 3: Apply for Co-Pay Assistance

Once approved, commercial plan members should enroll in the Eliquis 360 Support co-pay program before the first fill. Enrollment takes roughly 10 minutes online and the card activates immediately. The $10/month offer requires the co-pay card to be presented at the pharmacy alongside the insurance information. [9]

Step 4: Use a 90-Day Mail-Order Supply

Most Regence plans offer reduced cost-sharing when members use the plan's preferred mail-order pharmacy for a 90-day supply versus 30-day retail fills. A 90-day supply through mail order can cut per-dose cost by 10 to 25% depending on plan design. Confirm mail-order eligibility with Regence member services.

Special Situations: Medicare, Medicaid, and Employer Plans

Medicare Advantage Members

Regence Medicare Advantage plans use a Part D formulary that is filed with and approved by CMS each plan year. Eliquis appears on most Regence MedAdvantage formularies at Tier 3 or Tier 4 with a PA requirement. The 2025 $2,000 annual Part D out-of-pocket cap under the Inflation Reduction Act means Medicare beneficiaries will not pay more than $2,000 per year across all Part D drugs, regardless of tier. [10]

Medicaid Members

Oregon Health Plan (OHP) and Washington Apple Health are state Medicaid programs that cover apixaban for certain indications, though prior authorization requirements are stricter and step therapy through warfarin is frequently required before Eliquis is approved. Regence does not administer most Medicaid programs directly, so members should contact their managed care organization directly for formulary details.

Large Employer Plans

Self-funded employer plans administered by Regence (ASO arrangements) set their own formularies, and tier placement for Eliquis may differ substantially from Regence's standard commercial formulary. HR benefits departments can provide the specific formulary document. The Employee Retirement Income Security Act (ERISA) governs appeal rights for self-funded plans and differs from ACA state-regulated plans in important ways. [19]

When Eliquis May Not Be the Right Anticoagulant

Eliquis is contraindicated in patients with active pathological bleeding and in patients with severe hypersensitivity reactions to apixaban. [6] Mechanical heart valve patients and those with moderate-to-severe mitral stenosis should use warfarin, not a DOAC, per FDA labeling and AHA/ACC guidelines. [20] Pregnancy is a relative contraindication. The FDA prescribing information notes that apixaban crosses the placenta in animal studies, and safety in human pregnancy has not been established. [6]

Patients with severe hepatic impairment (Child-Pugh Class C) should avoid apixaban because hepatic metabolism via CYP3A4 and P-glycoprotein pathways is significantly altered. [6] Drug interactions with strong dual CYP3A4 and P-gp inhibitors (such as ketoconazole, itraconazole, and ritonavir) require dose reduction or avoidance per FDA labeling. [6]

Reversal Agent Availability

One clinical consideration that affects prescribing and insurer formulary decisions is the availability of a reversal agent for apixaban. Andexanet alfa (Andexxa), a recombinant Factor Xa decoy protein, reverses apixaban anticoagulation and received FDA approval in May 2018. [21] The ANNEXA-4 study (N=352) demonstrated effective or excellent hemostatic efficacy in 82% of patients with acute major bleeding on apixaban or rivaroxaban. [22] Andexanet alfa is expensive and not universally stocked, which is a consideration in procedural settings. Idarucizumab (Praxbind) reverses dabigatran but does not work for Factor Xa inhibitors like apixaban.